Systemic Lupus Erythematosus
The Systemic Lupus Erythematosus pipeline: 59 tracked drugs, 4 approved for this indication.
4 approved / phase 45 Phase 314 Phase 26 Phase 1/226 Phase 14 preclinical / unstaged
Compare the share prices of listed companies in Systemic Lupus Erythematosus →
Total attributable cost
$1.8B
$8,920/patient
Drug spend
Not yet sourced
All adult and pediatric SLE; 2018 population estimate · US
The Systemic Lupus Erythematosus pipeline
Key trial results for every approved and late-stage drug: Systemic Lupus Erythematosus results by drug.